BiomX Inc.Implements Reverse Stock Split and Stockholder Approval for Preferred Stock Conversion
BiomX Inc. a clinical-stage company specializing in phage therapies targeting pathogenic bacteria, recently announced a one-for-ten reverse stock split and stockholder approval for the conversion of outstanding Series X Convertible Preferred Stock to Common Stock.These strategic moves come as the company aims to optimize its capital structure and streamline operations.
The Reverse Stock Split, set to take effect on August 26, 2024, will see BiomX’s Common Stock trade on a split-adjusted basis under the existing symbol PHGE on the NYSE American.This decision was made in light of the company’s million shares outstanding and current price of $2, signaling a desire to enhance shareholder value and attract potential investors.
In conjunction with the Reverse Stock Split, BiomX received approval from stockholders to convert outstanding Series X Non-Voting Convertible Preferred Stock into shares of Common Stock.This conversion, approved in a recent vote, will further simplify the company’s capital structure and provide more flexibility for future growth initiatives.
These strategic moves highlight BiomX’s commitment to maximizing shareholder value and positioning itself for continued success in the competitive biotech industry.By streamlining its capital structure and aligning its preferred and common stock, BiomX is poised to drive innovation and deliver value to investors and patients alike.
Whether you’re a current shareholder or a potential investor, BiomX’s recent announcements are worth keeping an eye on as the company continues to advance its novel phage therapies and make a lasting impact in the healthcare sector.
Comments